Taking AIM at serious illness: implementing an access to investigational medicines expanded access program

When seriously ill patients have exhausted all treatment options available as part of usual care, the use of investigational agents may be warranted. Food and Drug Administration’s (FDA) Expanded Access (EA) pathway provides a mechanism for these patient’s physicians to pursue use of an investigatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Joly, Meghan Morrison, Edwards, Terri L., Jerome, Rebecca N., Mainor, Alex, Bernard, Gordon R., Pulley, Jill M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590908/
https://www.ncbi.nlm.nih.gov/pubmed/37877021
http://dx.doi.org/10.3389/fmed.2023.1287449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590908/
https://www.ncbi.nlm.nih.gov/pubmed/37877021
http://dx.doi.org/10.3389/fmed.2023.1287449

Ejemplares similares